BOSTON, May 18 (Reuters) – A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version of its anti-constipation drug Amitiza through an anticompetitive scheme.
(Reporting by Nate Raymond in Boston; Editing by Chris Reese)
Comments